| 1 |
Preclinical study supporting IND clearance for phase 2 clinical trial of HBPB1-007 peptide eye-drop therapy in geographic atrophy secondary to age-related macular degeneration |
| rProtein |
Geographic Atrophy secondary to dry Age-related Macular Degeneration |
TIR domain of Toll-like receptor (TLR) and its adaptor proteins |
Preclinical |
Huons BioPharma |
RS-2026-25502083 |
|
| 2 |
Development of BET protein inhibitory macular degeneration treatment that simultaneously targets neovascularization and inflammation inhibition |
| Small molecules |
Age-related Macular Degeneration |
BRD2 |
Preclinical |
BENOBIO Co., Ltd. |
RS-2024-00338382 |
|
| 3 |
Investigational New Drug Application Profiling of CGK012, a PKCα activator, for treating age.related macular degeneration |
| Small molecules |
Macular degeneration |
Protein kinase Cα / Wnt/β.catenin 신호전달 저해 |
Preclinical |
AREZ |
RS-2023-00259081 |
|
| 4 |
Non-clinical research for the development of dry macular degeneration |
| Small molecules |
Dry AMD |
RIPK1 |
Preclinical |
Mother’s Pharmaceutical Co., Ltd |
RS-2023-00219642 |
|
| 5 |
Development of DWRX2008 as a Novel Therapeutic for Intractable Ocular Angiogenesis |
| Small molecules |
Diabetic Retinopathy |
SGLT2 |
Preclinical |
Daewoong Therapeutics |
HN22C0450 |
|
| 6 |
Non-clinical development of gene therapy for Retinitis Pigmentosa with an RNA repair mechanism using AAV vector that encodes trans-splicing ribozyme targeting rhodopsin RNA |
| Gene & Nucleic acids |
Autosomal dominant Retinitis pigmentosa (adRP) |
P23H |
Preclinical |
Rznomics Inc. |
HN22C0300 |
|
| 7 |
CRG-02: An AAV-based anti-VEGF gene therapy for angiogenic ocular conditions delivered via intravitreal injection |
| Gene & Nucleic acids |
Macular Degeneration |
sVGFR1 |
Preclinical |
CdmoGen |
HN22C0190 |
|